Your browser doesn't support javascript.
loading
Expanding the ligandable proteome by paralog hopping with covalent probes.
Zhang, Yuanjin; Liu, Zhonglin; Hirschi, Marsha; Brodsky, Oleg; Johnson, Eric; Won, Sang Joon; Nagata, Asako; Petroski, Matthew D; Majmudar, Jaimeen D; Niessen, Sherry; VanArsdale, Todd; Gilbert, Adam M; Hayward, Matthew M; Stewart, Al E; Nager, Andrew R; Melillo, Bruno; Cravatt, Benjamin.
Afiliação
  • Zhang Y; Department of Chemistry, The Scripps Research Institute, La Jolla, CA 92037 USA.
  • Liu Z; Department of Chemistry, The Scripps Research Institute, La Jolla, CA 92037 USA.
  • Hirschi M; Medicine Design, Pfizer Research and Development, Pfizer Inc., La Jolla, CA 92121, USA.
  • Brodsky O; Medicine Design, Pfizer Research and Development, Pfizer Inc., La Jolla, CA 92121, USA.
  • Johnson E; Medicine Design, Pfizer Research and Development, Pfizer Inc., La Jolla, CA 92121, USA.
  • Won SJ; Department of Chemistry, The Scripps Research Institute, La Jolla, CA 92037 USA.
  • Nagata A; Medicine Design, Pfizer Research and Development, Pfizer Inc., La Jolla, CA 92121, USA.
  • Petroski MD; Oncology Research and Development, Pfizer Inc., La Jolla, CA 92121, USA.
  • Majmudar JD; Discovery Sciences, Pfizer Research and Development, Pfizer Inc., Cambridge, MA 02139, USA.
  • Niessen S; Oncology Research and Development, Pfizer Inc., La Jolla, CA 92121, USA.
  • VanArsdale T; Current address: Belharra Therapeutics, 3985 Sorrento Valley Blvd suite c, San Diego, CA 92121.
  • Gilbert AM; Oncology Research and Development, Pfizer Inc., La Jolla, CA 92121, USA.
  • Hayward MM; Discovery Sciences, Pfizer Research and Development, Pfizer Inc., Groton, CT 06340, USA.
  • Stewart AE; Discovery Sciences, Pfizer Research and Development, Pfizer Inc., Groton, CT 06340, USA.
  • Nager AR; Current address: Magnet Biomedicine, 321 Harrison Ave., Suite 600, Boston, MA 02118, USA.
  • Melillo B; Medicine Design, Pfizer Research and Development, Pfizer Inc., La Jolla, CA 92121, USA.
  • Cravatt B; Oncology Research and Development, Pfizer Inc., La Jolla, CA 92121, USA.
bioRxiv ; 2024 Jan 19.
Article em En | MEDLINE | ID: mdl-38293178
ABSTRACT
More than half of the ~20,000 protein-encoding human genes have at least one paralog. Chemical proteomics has uncovered many electrophile-sensitive cysteines that are exclusive to a subset of paralogous proteins. Here, we explore whether such covalent compound-cysteine interactions can be used to discover ligandable pockets in paralogs that lack the cysteine. Leveraging the covalent ligandability of C109 in the cyclin CCNE2, we mutated the corresponding residue in paralog CCNE1 to cysteine (N112C) and found through activity-based protein profiling (ABPP) that this mutant reacts stereoselectively and site-specifically with tryptoline acrylamides. We then converted the tryptoline acrylamide-N112C-CCNE1 interaction into a NanoBRET-ABPP assay capable of identifying compounds that reversibly inhibit both N112C- and WT-CCNE1CDK2 complexes. X-ray crystallography revealed a cryptic allosteric pocket at the CCNE1CDK2 interface adjacent to N112 that binds the reversible inhibitors. Our findings thus provide a roadmap for leveraging electrophile-cysteine interactions to extend the ligandability of the proteome beyond covalent chemistry.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article